Sort
30,917 grants matching “tumor microenvironment”
Enhancing Cancer Immunotherapy: Targeting the Tumor and Targeting the Host
$820,359Ronald Levy · Stanford University · R35 · FY2022 · CA
Interdisciplinary Small Animal Imaging for Oncology
$820,241Johns Hopkins University · R24 · FY2005 · CA
Molecular Determinants and Therapeutic Consequences of Immune Heterogeneity in Cancer
$820,052Robert H Vonderheide · University Of Pennsylvania · R01 · FY2020 · CA
Enabling immunotherapy for high-risk Group 3 medulloblastoma via systems immunology
$819,000Hongbo Chi · St. Jude Children'S Research Hospital · U01 · FY2025 · CA
Enabling immunotherapy for high-risk Group 3 medulloblastoma via systems immunology
$819,000Hongbo Chi · St. Jude Children'S Research Hospital · U01 · FY2023 · CA
Fibroblast Heterogeneity in Pancreatic Cancer
$818,876David Tuveson · Cold Spring Harbor Laboratory · R01 · FY2021 · CA
Targeting the Plasminogen Activation System to Limit Pancreatic Cancer Progression and Associated Thrombosis
$818,452Matthew J. Flick · Cincinnati Childrens Hosp Med Ctr · U01 · FY2018 · HL
Pancreatic Tumor Micro-environment Network
$818,351Surinder Kumar Batra · University Of Nebraska Medical Center · U54 · FY2012 · CA
Cancer Center Administration
$818,343Peter A Jones · University Of Southern California · P30 · FY2008 · CA
Pancreatic Cancer Detection Consortium
$817,862Michael A Hollingsworth · University Of Nebraska Medical Center · U01 · FY2025 · CA
Systematic identification of oncogenic KRAS synthetic lethal interactions
$817,805William C Hahn · Broad Institute, Inc. · U01 · FY2015 · CA
Impairment of anti-Plasmodium T cell memory by type I Interferon Signaling
$817,729Nana Kwaku Minkah · Seattle Children'S Hospital · R01 · FY2023 · AI
TGF-betas in breast cancer progression
$817,677Lalage Wakefield · Division Of Basic Sciences - Nci · ZIA · FY2010 · CA
Mechanobiology
$817,653Alexander Cartagena-Rivera · National Institute Of Biomedical Imaging And Bioengineering · ZIA · FY2021 · EB
Cancer Biology
$817,328Vito Quaranta · Vanderbilt University · U54 · FY2008 · CA
Bispecific Antibody Therapeutics for Neuroblastoma and Diffuse Midline Glioma
$817,202James M Olson · Seattle Children'S Hospital · U01 · FY2024 · CA
Host factors, tumor microenvironment and survival in a multiethnic study of Hodgkin lymphoma patients
$816,487Wendy Cozen · University Of Southern California · R01 · FY2017 · CA
Immune epigenetic biomarkers of survival in glioma epidemiology
$815,423John K. Wiencke · University Of California, San Francisco · R01 · FY2018 · CA
Image-based models of tumor-immune dynamics in glioblastoma
$814,918Kristin R Swanson · Mayo Clinic Arizona · U01 · FY2022 · CA
Uncovering the Biology of Resistance to Tyrosine Kinase Inhibitors in EGFR Mutant Lung Cancer Patient-Derived Models.
$814,050Katerina Abigail Politi · Yale University · U01 · FY2019 · CA
Glutamine metabolism inhibitors for TB and TB-HIV: dual action as host-directed therapies with antibacterial activity
$813,838William Ramses Bishai · Johns Hopkins University · R01 · FY2024 · AI
Glutamine metabolism inhibitors for TB and TB-HIV: dual action as host-directed therapies with antibacterial activity
$813,838William Ramses Bishai · Johns Hopkins University · R01 · FY2023 · AI
Glutamine metabolism inhibitors for TB and TB-HIV: dual action as host-directed therapies with antibacterial activity
$813,838William Ramses Bishai · Johns Hopkins University · R01 · FY2022 · AI
Glutamine metabolism inhibitors for TB and TB-HIV: dual action as host-directed therapies with antibacterial activity
$813,838William Ramses Bishai · Johns Hopkins University · R01 · FY2021 · AI
Systematic Characterization and Targeting of Neomorphic Drivers in Cancer
$813,823Gordon B. Mills · Oregon Health & Science University · U01 · FY2024 · CA